EXCLUSIVE: Ocean Biomedical Announces New Patent For Fibrosis Candidate Catering To One Of Leading Death Causes In US
Portfolio Pulse from Vandana Singh
Ocean Biomedical Inc (NASDAQ:OCEA) has been granted a patent by the United States Patent and Trademark Office for its anti-Chitinase 1 small molecule candidate, a key factor in controlling and inhibiting fibrosis progression. The patent covers potential applications in several major fibrotic diseases. Ocean Biomedical is the exclusive licensee of this patent family. The company's approach has shown an 85%-90% reduction in collagen accumulation in four different pulmonary fibrosis animal models.
August 29, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocean Biomedical Inc has been granted a patent for its anti-Chitinase 1 small molecule candidate. This could potentially increase the company's value and attract more investors.
The granting of a patent to Ocean Biomedical Inc for its anti-Chitinase 1 small molecule candidate could potentially increase the company's value as it provides a competitive advantage and opens up new opportunities for the treatment of several major fibrotic diseases. This could attract more investors, potentially leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100